long term effects of glp 1 agonists Frontiers Part 2 of a 3-Part

These include limited long-term safety data across diverse populations, insufficient understanding of mechanisms in neuropsychiatric and oncologic contexts, and suboptimal communication between clinicians and patients

Therefore, if a new oral drug in development is intended to be co-administered with a GLP-1 agonist, we highly recommend conducting a healthy volunteer drug-drug interaction prior to Phase 3 trials to characterize the impact on the PK of the candidate new drug

Lingvay I, Sumithran P, Cohen RV, le Roux CW

Here is a small sampling of the research evidence: A 2012 meta-analysis examined 25 randomized controlled trials and found that GLP-1 receptor agonist treatment caused weight loss

In the group that compared SGLT2i to placebo, the HbA1c estimates were of moderate certainty due to unclear selection bias results in two papers

Brown JC